Galenica AG Sees Record Sales Growth to Over CHF 4 Billion

In 2025, Galenica AG reported a 5.5% increase in sales, reaching CHF 4,135.6 million. This marks the highest sales level in the company's history. All business areas contributed to this growth, with strong performances in prescription medications and dietary supplements leading the charge.

The company's pharmacy business expanded with 5 new locations, bringing the total to 381 pharmacies, while reinforcing their role as primary healthcare points in Switzerland. Additionally, the new "Diagnostics" division, introduced following the acquisition of Labor Team, added 1% to overall sales growth.

Galenica confirmed an anticipated EBIT growth of 10-12% for 2025. Despite challenges, the "Products & Brands" segment grew by 6.2%, while the "Logistics & IT" segment also saw a 4.8% increase, aligning with overall market trends. A renewed focus on a comprehensive customer experience, both online and offline, supported these advancements.